Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: melanomaulnconcurrentenrollmentstage
  Phrases that lowered it: with historypatientsmclfree ofhistory of
• Sponsor's past termination rate: 3.9% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 335 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 81 (lowers risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 16 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery NCT01701037 · started 2013 · scored riskier than 71% of active trials terminated
• Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma NCT01972347 · started 2014 · scored riskier than 96% of active trials completed
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). NCT01682083 · started 2013 · scored riskier than 93% of active trials completed
• Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma NCT02200562 · started 2014 · scored riskier than 85% of active trials terminated
• Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients NCT02296996 · started 2014 · scored riskier than 69% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.